ERC1671 + sargramostim + cyclophosphamide + bevacizumab + pembrolizumab

This is a **combination therapy** consisting of ERC1671 (also known as Gliovac, a vaccine composed of allogeneic and autologous glioma cell lysates), **sargramostim** (a recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), **cyclophosphamide** (an alkylating chemotherapeutic and immunosuppressive agent), **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A, VEGF-A), and **pembrolizumab** (a monoclonal antibody PD-1 immune checkpoint inhibitor). The combination is being investigated for synergistic effects in treating **malignant gliomas (glioblastoma)**, leveraging direct immunogenic tumor cell lysate vaccination (ERC1671), immune cell recruitment and stimulation (sargramostim), suppression of regulatory T cells to enhance vaccine response (cyclophosphamide), inhibition of tumor angiogenesis (bevacizumab), and immune checkpoint blockade (pembrolizumab). Each agent has a known and distinct mechanism of action, combining immune stimulation, tumor cell killing, and anti-angiogenic/immunotherapy strategies.

Other names

ERC1671ERC-1671ERC 1671sargramostimcyclophosphamidebevacizumabpembrolizumab